Cargando…
Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
Cardiac failure is a major cause of mortality in patients with Duchenne muscular dystrophy (DMD). Antisense-mediated exon skipping has the ability to correct out-of-frame mutations in DMD to produce truncated but functional dystrophin. Traditional antisense approaches have however been limited by th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005479/ https://www.ncbi.nlm.nih.gov/pubmed/29912990 http://dx.doi.org/10.1371/journal.pone.0198897 |
_version_ | 1783332687703965696 |
---|---|
author | Blain, Alison M. Greally, Elizabeth McClorey, Graham Manzano, Raquel Betts, Corinne A. Godfrey, Caroline O’Donovan, Liz Coursindel, Thibault Gait, Mike J. Wood, Matthew J. MacGowan, Guy A. Straub, Volker W. |
author_facet | Blain, Alison M. Greally, Elizabeth McClorey, Graham Manzano, Raquel Betts, Corinne A. Godfrey, Caroline O’Donovan, Liz Coursindel, Thibault Gait, Mike J. Wood, Matthew J. MacGowan, Guy A. Straub, Volker W. |
author_sort | Blain, Alison M. |
collection | PubMed |
description | Cardiac failure is a major cause of mortality in patients with Duchenne muscular dystrophy (DMD). Antisense-mediated exon skipping has the ability to correct out-of-frame mutations in DMD to produce truncated but functional dystrophin. Traditional antisense approaches have however been limited by their poor uptake into cardiac muscle. The addition of cell-penetrating peptides to antisense molecules has increased their potency and improved their uptake into all muscles, including the heart. We have investigated the efficacy of the Peptide-conjugated phosphodiamidate morpholino oligomer (P-PMO) Pip6a-PMO, for restoration of cardiac dystrophin and functional rescue in DMD mice- the mdx mouse and the less well characterised Cmah-/-mdx mouse (which carry a human-like mutation in the mouse Cmah gene as well as a mutation in DMD). In our first study male mdx mice were administered Pip6a-PMO, i.v, fortnightly from 12 to 30 weeks of age alongside mock-injected age-matched mdx and C57BL10 controls. Mice received 4 doses of 18 mg/kg followed by 8 doses of 12.5 mg/kg. The cardiac function of the mice was analysed 2 weeks after their final injection by MRI followed by conductance catheter and their muscles were harvested for dystrophin quantification. In the second study, male Cmah-/-mdx mice, received 12.5 mg/kg Pip6a-PMO, i.v fortnightly from 8 to 26 weeks and assessed by MRI at 3 time points (12, 18 and 28 weeks) alongside mock-injected age-matched mdx, C57BL10 and Cmah-/-mdx controls. The mice also underwent MEMRI and conductance catheter at 28 weeks. This allowed us to characterise the cardiac phenotype of Cmah-/-mdx mice as well as assess the effects of P-PMO on cardiac function. Pip6a-PMO treatment resulted in significant restoration of dystrophin in mdx and Cmah-/-mdx mice (37.5% and 51.6%, respectively), which was sufficient to significantly improve cardiac function, ameliorating both right and left ventricular dysfunction. Cmah-/-mdx mice showed an abnormal response to dobutamine stress test and this was completely ameliorated by PIP6a-PMO treatment. These encouraging data suggest that total restoration of dystrophin may not be required to significantly improve cardiac outcome in DMD patients and that it may be realistic to expect functional improvements with modest levels of dystrophin restoration which may be very achievable in future clinical trials. |
format | Online Article Text |
id | pubmed-6005479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-60054792018-06-25 Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy Blain, Alison M. Greally, Elizabeth McClorey, Graham Manzano, Raquel Betts, Corinne A. Godfrey, Caroline O’Donovan, Liz Coursindel, Thibault Gait, Mike J. Wood, Matthew J. MacGowan, Guy A. Straub, Volker W. PLoS One Research Article Cardiac failure is a major cause of mortality in patients with Duchenne muscular dystrophy (DMD). Antisense-mediated exon skipping has the ability to correct out-of-frame mutations in DMD to produce truncated but functional dystrophin. Traditional antisense approaches have however been limited by their poor uptake into cardiac muscle. The addition of cell-penetrating peptides to antisense molecules has increased their potency and improved their uptake into all muscles, including the heart. We have investigated the efficacy of the Peptide-conjugated phosphodiamidate morpholino oligomer (P-PMO) Pip6a-PMO, for restoration of cardiac dystrophin and functional rescue in DMD mice- the mdx mouse and the less well characterised Cmah-/-mdx mouse (which carry a human-like mutation in the mouse Cmah gene as well as a mutation in DMD). In our first study male mdx mice were administered Pip6a-PMO, i.v, fortnightly from 12 to 30 weeks of age alongside mock-injected age-matched mdx and C57BL10 controls. Mice received 4 doses of 18 mg/kg followed by 8 doses of 12.5 mg/kg. The cardiac function of the mice was analysed 2 weeks after their final injection by MRI followed by conductance catheter and their muscles were harvested for dystrophin quantification. In the second study, male Cmah-/-mdx mice, received 12.5 mg/kg Pip6a-PMO, i.v fortnightly from 8 to 26 weeks and assessed by MRI at 3 time points (12, 18 and 28 weeks) alongside mock-injected age-matched mdx, C57BL10 and Cmah-/-mdx controls. The mice also underwent MEMRI and conductance catheter at 28 weeks. This allowed us to characterise the cardiac phenotype of Cmah-/-mdx mice as well as assess the effects of P-PMO on cardiac function. Pip6a-PMO treatment resulted in significant restoration of dystrophin in mdx and Cmah-/-mdx mice (37.5% and 51.6%, respectively), which was sufficient to significantly improve cardiac function, ameliorating both right and left ventricular dysfunction. Cmah-/-mdx mice showed an abnormal response to dobutamine stress test and this was completely ameliorated by PIP6a-PMO treatment. These encouraging data suggest that total restoration of dystrophin may not be required to significantly improve cardiac outcome in DMD patients and that it may be realistic to expect functional improvements with modest levels of dystrophin restoration which may be very achievable in future clinical trials. Public Library of Science 2018-06-18 /pmc/articles/PMC6005479/ /pubmed/29912990 http://dx.doi.org/10.1371/journal.pone.0198897 Text en © 2018 Blain et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Blain, Alison M. Greally, Elizabeth McClorey, Graham Manzano, Raquel Betts, Corinne A. Godfrey, Caroline O’Donovan, Liz Coursindel, Thibault Gait, Mike J. Wood, Matthew J. MacGowan, Guy A. Straub, Volker W. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy |
title | Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy |
title_full | Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy |
title_fullStr | Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy |
title_full_unstemmed | Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy |
title_short | Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy |
title_sort | peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and cmah-/-mdx mouse models of duchenne muscular dystrophy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005479/ https://www.ncbi.nlm.nih.gov/pubmed/29912990 http://dx.doi.org/10.1371/journal.pone.0198897 |
work_keys_str_mv | AT blainalisonm peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT greallyelizabeth peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT mccloreygraham peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT manzanoraquel peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT bettscorinnea peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT godfreycaroline peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT odonovanliz peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT coursindelthibault peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT gaitmikej peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT woodmatthewj peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT macgowanguya peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy AT straubvolkerw peptideconjugatedphosphodiamidateoligomermediatedexonskippinghasbenefitsforcardiacfunctioninmdxandcmahmdxmousemodelsofduchennemusculardystrophy |